Clinical trial register · China

Clinical Trials in Huizhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC

19224

Studies in scope

all four open statuses

11811

Recruiting now

open to new participants

2030

Lead sponsors

across recruiting studies

Top sites

Beijing 56 Guangzhou 46 Shanghai 28 Wuhan 26 Changsha 22

Narrow the registerReset

Search within results

Recruitment status

Phase

Lead sponsor

Clear sponsor filter

Site location

All 65 locations

Target enrolment

Trials with a site in Huizhou

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Recruiting

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity

NCT07874633Obesity, Overweight

DrugBerobenatide

Pfizer

Phase 3

432

Hefei, Beijing, Huizhou, Zhengzhou, Nanjing, Nanchang

2026-10-28

Recruiting

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

NCT07792954Obesity, Overweight

DrugBerobenatide

Pfizer

Phase 3

300

Hefei, Beijing, Chongqing, Huizhou, Hengshui, Shijiazhuang, Harbin, Luoyang

2026-09-24

Recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07363694Moderate to Severe Chronic Obstructive Pulmonary Disease

Pfizer

Phase 2/3

1,156

Chizhou, Fuyang, Hefei, Beijing, Chongqing, Guangzhou, Huizhou, Xinxiang

2026-02-11

Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsPF-08634404·Pembrolizumab

Pfizer

Phase 3

1,410

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Jiangmen, Nanning

2026-01-06

Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsSigvotatug vedotin·Pembrolizumab

Pfizer

Phase 3

714

Hefei, Beijing, Fuzhou, Guangzhou, Huizhou, Nanning, Harbin, Luoyang

2025-07-23

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/city/huizhou

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5 of those studies with a site in Huizhou that also match the filters currently applied.

How many clinical trials are recruiting in Huizhou?

5 of the 5 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Huizhou), 5 studies
Phase	Studies	Recruiting	Share
Phase 3	4	4	80%
Phase 2/3	1	1	20%

Most active sponsors

Lead sponsors with the most studies (Huizhou)
Lead sponsor	Studies	Recruiting
Pfizer	5	5

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.